Cargando…
Use of PEGylated Recombinant Human Growth Hormone in Chinese Children with Growth Hormone Deficiency: A 24-Month Follow-Up Study
OBJECTIVE: Once-weekly PEGylated recombinant human growth hormone (rhGH) is the sole long-acting GH formulation available currently for pediatric patients with GH deficiency (GHD). The aim of this study was to evaluate the efficacy and safety of PEGylated rhGH therapy compared to daily rhGH therapy...
Autores principales: | Qiao, Yu, Wang, Zengmin, Han, Jinyan, Li, Guimei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770346/ https://www.ncbi.nlm.nih.gov/pubmed/31641350 http://dx.doi.org/10.1155/2019/1438723 |
Ejemplares similares
-
Growth and Adult Height during Human Growth Hormone Treatment in Chinese Children with Multiple Pituitary Hormone Deficiency Caused by Pituitary Stalk Interruption Syndrome: A Single Centre Study
por: Wang, Fengxue, et al.
Publicado: (2020) -
Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015) -
Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency
por: Liang, Shuang, et al.
Publicado: (2018) -
Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies
por: Luo, Xiaoping, et al.
Publicado: (2017) -
The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022)